[Correspondence] Clonal hematopoiesis and atherosclerosis

Phillips, Rupert, Chaudry, Sabah and Chevassut, Timothy (2017) [Correspondence] Clonal hematopoiesis and atherosclerosis. New England Journal of Medicine, 377 (14). pp. 1400-1402. ISSN 0028-4793

[img] PDF (Letter) - Published Version
Available under License All Rights Reserved.

Download (77kB)

Abstract

Jaiswal et al. report the results of four case–control studies that confirm a near doubling in the risk of coronary heart disease in patients with CHIP,1 a finding that was first reported in the Journal in 2014.2 The authors postulate that two mechanisms may be involved: the promotion of inflammatory responses, as supported in a study involving Tet2 knockout mice, and an increase in the number of myeloid cells, a finding that appears to be more relevant for patients with JAK2 mutations, which confer a much larger risk than the more common DNMT3A, TET2, and ASXL1 mutations, in which blood counts remain normal. However, the authors do not provide data relating to red-cell distribution width, which is the only blood-cell index that has been shown to have a significant association with CHIP2 and which has been associated with an unexplained increase in all-cause mortality in an aging population. 3,4 In understanding how CHIP promotes atherosclerosis, it is important to explore the causal relationship between clonal hematopoiesis and red-cell anisocytosis to determine whether these are independent or associated risk factors for cardiovascular disease.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Research Centres and Groups: Haematology Research Group
Subjects: R Medicine
R Medicine > RC Internal medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Depositing User: Timothy Chevassut
Date Deposited: 04 Jun 2018 10:00
Last Modified: 12 Jul 2019 16:00
URI: http://sro.sussex.ac.uk/id/eprint/76279

View download statistics for this item

📧 Request an update